Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine chelates gadolinium, a paramagnetic metal ion. After injection, the complex shortens the T1 relaxation time of nearby water protons, producing a brighter signal on T1‑weighted MRI sequences. This increased signal intensity highlights vascular and tissue structures, allowing more detailed diagnostic images.

The dose of Multihance is determined by the prescribing physician based on the patient’s body weight, renal function and the specific imaging protocol. Typical dosing follows established guidelines for gadolinium contrast agents, but exact amounts are individualized and should be set by the radiologist or ordering clinician.

Safety data for gadobenate dimeglumine during pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential diagnostic benefit outweighs any possible risk to the fetus. Breastfeeding mothers should discuss potential exposure with their healthcare provider, as the drug may be excreted in milk.

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Multihance (gadobenate dimeglumine) is a macrocyclic gadolinium agent with a higher relaxivity than many conventional agents, providing stronger signal enhancement at lower doses. Compared with linear agents, it has a lower risk of nephrogenic systemic fibrosis, especially in patients with moderate renal function, while offering comparable image quality for vascular and tissue imaging.

Multihance must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. If the product reaches room temperature, it may be used for a limited period as indicated in the product labeling, but should be returned to refrigeration promptly.

Multihance is administered as an intravenous injection, typically through a peripheral vein. The injection is performed by a qualified healthcare professional, often using a power injector to deliver the contrast at a controlled rate that matches the imaging protocol. The exact administration technique is determined by the radiology department’s standard procedures.

The most serious risks associated with Multihance include severe allergic reactions such as anaphylaxis, nephrogenic systemic fibrosis in patients with severe renal impairment, acute hypotension or cardiovascular collapse, and life‑threatening respiratory distress. Immediate medical attention is required if any of these reactions occur during or after administration.

Multihance should be avoided in patients with known hypersensitivity to gadobenate dimeglumine or any component of the formulation. It is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of nephrogenic systemic fibrosis, and it should be used with caution in pregnant or breastfeeding women when the benefit justifies the potential risk.